GMAB.CO

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

Genmab A/S (GMAB.CO) is a healthcare company listed on Nasdaq Copenhagen, traded in DKK. Over the past year it moved between DKK 1,512.00 and DKK 3,947.00.

• Healthcare
• Biotechnology
• Copenhagen, Denmark
• 3.1K employees
• Led by Jan G.J. van de Winkel Ph.D.